Literature DB >> 30303126

Opportunities and priorities for breast surgical research.

Ramsey I Cutress1, Stuart A McIntosh2, Shelley Potter3, Amit Goyal4, Cliona C Kirwan5, James Harvey5, Adele Francis6, Amtul R Carmichael7, Raghavan Vidya8, Jayant S Vaidya9, Patricia Fairbrother10, John R Benson11, Malcolm W R Reed12.   

Abstract

The 2013 Breast Cancer Campaign gap analysis established breast cancer research priorities without a specific focus on surgical research or the role of surgeons on breast cancer research. This Review aims to identify opportunities and priorities for research in breast surgery to complement the 2013 gap analysis. To identify these goals, research-active breast surgeons met and identified areas for breast surgery research that mapped to the patient pathway. Areas included diagnosis, neoadjuvant treatment, surgery, adjuvant therapy, and attention to special groups (eg, those receiving risk-reducing surgery). Section leads were identified based on research interests, with invited input from experts in specific areas, supported by consultation with members of the Association of Breast Surgery and Independent Cancer Patients' Voice groups. The document was iteratively modified until participants were satisfied that key priorities for surgical research were clear. Key research gaps included issues surrounding overdiagnosis and treatment; optimising treatment options and their selection for neoadjuvant therapies and subsequent surgery; reducing rates of re-operations for breast-conserving surgery; generating evidence for clinical effectiveness and cost-effectiveness of breast reconstruction, and mechanisms for assessing novel interventions; establishing optimal axillary management, especially post-neoadjuvant treatment; and defining and standardising indications for risk-reducing surgery. We propose strategies for resolving these knowledge gaps. Surgeons are ideally placed for a central role in breast cancer research and should foster a culture of engagement and participation in research to benefit patients and health-care systems. Development of infrastructure and surgical research capacity, together with appropriate allocation of research funding, is needed to successfully address the key clinical and translational research gaps that are highlighted in this Review within the next two decades.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30303126     DOI: 10.1016/S1470-2045(18)30511-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  10 in total

1.  Economic Impact of Reducing Reexcision Rates after Breast-Conserving Surgery in a Large, Integrated Health System.

Authors:  Jeffery M Chakedis; Annie Tang; Alison Savitz; Liisa L Lyon; Patricia E Palacios; Brooke Vuong; Maihgan A Kavanagh; Gillian E Kuehner; Sharon B Chang
Journal:  Ann Surg Oncol       Date:  2022-07-29       Impact factor: 4.339

2.  A Meta-analysis of Clinical, Patient-Reported Outcomes and Cost of DIEP versus Implant-based Breast Reconstruction.

Authors:  Ankur Khajuria; Max Prokopenko; Max Greenfield; Oliver Smith; Andrea L Pusic; Afshin Mosahebi
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-10-28

3.  Patient and public priorities for breast cancer research: a qualitative study in the UK.

Authors:  George Boundouki; Rebecca Wilson; Paula Duxbury; Julia Henderson; Laura Ballance; Julie Wray; Vivienne Appanah; Ibrahim Ibrahim; James Harvey; Cliona Clare Kirwan
Journal:  BMJ Open       Date:  2021-01-29       Impact factor: 2.692

4.  Protocol for a mixed-method study to inform the feasibility of undertaking a large-scale multicentre study comparing the clinical and patient-reported outcomes of oncoplastic breast conservation as an alternative to mastectomy with or without immediate breast reconstruction in women unsuitable for standard breast-conserving surgery (the ANTHEM Feasibility Study).

Authors:  Charlotte Davies; Christopher Holcombe; Joanna Skillman; Lisa Whisker; William Hollingworth; Carmel Conefrey; Nicola Mills; Paul White; Charles Comins; Douglas Macmillan; Patricia Fairbrother; Shelley Potter
Journal:  BMJ Open       Date:  2021-04-16       Impact factor: 2.692

5.  The challenge of equipoise: qualitative interviews exploring the views of health professionals and women with multiple ipsilateral breast cancer on recruitment to a surgical randomised controlled feasibility trial.

Authors:  Jenny Ingram; Lucy Beasant; John Benson; Adrian Murray Brunt; Anthony Maxwell; James Richard Harvey; Rosemary Greenwood; Nicholas Roberts; Norman Williams; Debbie Johnson; Zoe Winters
Journal:  Pilot Feasibility Stud       Date:  2022-02-28

6.  Novel multifunctional NIR-II aggregation-induced emission nanoparticles-assisted intraoperative identification and elimination of residual tumor.

Authors:  Qiaojun Qu; Zeyu Zhang; Xiaoyong Guo; Junying Yang; Caiguang Cao; Changjian Li; Hui Zhang; Pengfei Xu; Zhenhua Hu; Jie Tian
Journal:  J Nanobiotechnology       Date:  2022-03-19       Impact factor: 10.435

7.  Analysis of the Risk Factors for Elevated D-Dimer Level After Breast Cancer Surgery: A Multicenter Study Based on Nursing Follow-Up Data.

Authors:  Yanqiu Wang; Xi Liang; Shujun Wang; Yuying Wang; Ling Qin; Danni Chen; Yanlin Jiang; Hao Zhang
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

8.  Osteoglycin (OGN) Inhibits Cell Proliferation and Invasiveness in Breast Cancer via PI3K/Akt/mTOR Signaling Pathway.

Authors:  Tao Xu; Rui Zhang; Menglu Dong; Zeyu Zhang; Hanning Li; Chenao Zhan; Xingrui Li
Journal:  Onco Targets Ther       Date:  2019-12-04       Impact factor: 4.147

9.  International development and implementation of a core measurement set for research and audit studies in implant-based breast reconstruction: a study protocol.

Authors:  Shelley Potter; Charlotte Davies; Christopher Holcombe; Eva Weiler-Mithoff; Joanna Skillman; Raghavan Vidya; Yazan Masannat; Walter Weber; Joerg Heil; Sherif Wilson; Steven Thrush; Lisa Whisker; Jane Blazeby; Chris Metcalfe; Kerry Avery
Journal:  BMJ Open       Date:  2020-01-20       Impact factor: 2.692

10.  Long-Chain Non-Coding SOX21-AS1 Promotes Proliferation and Migration of Breast Cancer Cells Through the PI3K/AKT Signaling Pathway.

Authors:  Xiu-Yun Sheng; Cheng-Hong Wang; Chun-Feng Wang; Hong-Yan Xu
Journal:  Cancer Manag Res       Date:  2020-11-02       Impact factor: 3.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.